viewLexaria Bioscience Corp.

Lexaria Bioscience taps a former Altria Group executive to join its board of directors

Brian Quigley, a 16-year veteren of Lexaria investor Altria Group, is joining the company's board

Lexaria Bioscience Corp -
In March, Quigley left Altria to co-found Green Sky Strategy, a cannabis-centric strategic advisory company

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), the biotechnology company behind the drug delivery system DehydraTECH, tapped a new director on Wednesday who recently left one of its major business partners. 

The company announced that Brian Quigley, a 16-year veteran of Altria Group, would be joining its board. Quigley spent a combined 7 years as CEO of Altria's subsidiaries US Smokeless Tobacco and then Nu-Mark, while an investment deal between the tobacco giant and Lexaria was being negotiated. 

In June, the companies announced that Altria would invest up to $12 million to fund a research and development program focused on using Lexaria’s technology to develop a safer way to ingest nicotine.

READ: Lexaria Bioscience secures cannabis R&D license from Health Canada

At Altria, Quigley oversaw regulatory environments for new and nicotine products and worked to implement harm reduction strategies. 

In March, Quigley left Altria to co-found Green Sky Strategy, a cannabis-centric strategic advisory company. All told, he has 20 years of consumer packaged goods experience over his career. 

“Lexaria continues to build towards its role as one of the world’s leading reduced harm nicotine delivery companies, and we welcome Brian’s expertise,” Chairman Chris Bunka said in a statement.

“His years of regulatory, product launch and Fortune-500 corporate experience will be an invaluable asset to Lexaria as we expand our presence in reduced-harm nicotine products around the world.”

Lexaria's DehydraTECH system works by helping the body absorb compounds faster and more effectively.

The company's shares declined 4.5% to C$1.06 and 5.9% $US0.80 on OTC Markets.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Lexaria Bioscience Corp.

Price: 0.41 CAD

Market: CSE
Market Cap: $33.1 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...



Full interview: Lexaria Bio Science working with frontline companies to...

Lexaria Bioscience (CSE:LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive in Vancouver to discuss the company commencing a program, in collaboration with leading laboratories in Canada and the U.S. to study the benefits of DehydraTECH  in the fight against coronavirus...

1 week, 5 days ago

2 min read